BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

ThromboGenics Ltd. 

1560 Broadway
10th Floor
Dublin  New York  10036  New York
Phone: 212-201-0920 Fax: 212-201-0921


SEARCH JOBS
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer. Our lead product, ocriplasmin (microplasmin), has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.

In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer, in partnership with Roche.

ThromboGenics currently has around 80 employees at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the United States. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.


 Key Statistics


Email:
Ownership: Public

Web Site: ThromboGenics Ltd.
Employees: 80
Symbol: THR.BR
 



Industry
Biotechnology






 Company News
ThromboGenics Ltd. (THR.BR)' JETREA® Available in Germany Public and Private Market 5/2/2013 9:30:21 AM    More...
ThromboGenics Ltd. (THR.BR)' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, Now Launched in the UK 4/11/2013 10:18:26 AM    More...
ThromboGenics Ltd. (THR.BR) Starts Trading as Part of the BEL20 Index Today 3/18/2013 9:43:56 AM    More...
ThromboGenics Ltd. (THR.BR) Transparency Declaration 7/13/2012 10:45:21 AM    More...
ThromboGenics Ltd. (THR.BR) Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin 6/7/2012 10:42:37 AM    More...
ThromboGenics Ltd. (THR.BR) Announces That the FDA Intends to Grant Ocriplasmin Priority Review 2/2/2012 9:46:32 AM    More...
ThromboGenics Ltd. (THR.BR) and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule 12/16/2011 10:29:14 AM    More...
ThromboGenics Ltd. (THR.BR) and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule 12/16/2011 7:20:56 AM    More...
ThromboGenics Ltd. (THR.BR) Hopes for Eye Treatment Launch in 2012 8/25/2011 8:07:15 AM    More...
ThromboGenics Ltd. (THR.BR)'s Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9/1/2010 6:32:22 AM    More...
12345678

//-->